Appenzell (ots) - Ergonex Pharma today announced that the United States Food and Drug Administration (FDA) has granted orphan drug designation to Terguride for the treatment of pulmonary arterial hypertension (PAH). Terguride is currently being evaluated for PAH in a pivotal Phase II trial in Europe. "The ...
Roche Professional Diagnostics
Rotkreuz, Switzerland (ots) - Roche Diagnostics announced today that the Elecsys Anti-HCV (Hepatitis C Virus) assay has received regulatory approval in Europe for the E 170 analyzer for MODULAR ANALYTICS and the e 601 module for the cobas 6000 platform. The Elecsys Anti-HCV assay is already available on the Elecsys 2010 and the cobas e 411 instruments. Hepatitis C virus (HCV) infection represents a major cause ...
Zürich (ots) - Solianis sees its Multi-Sensor Technology as a promising approach to continuous non-invasive glucose monitoring. Professor Marc Donath, member of the Solianis Scientific Advisory Board and Professor for endocrinology and diabetology at the University Hospital in Zürich, Switzerland, has ...
Lugano (ots) - Helsinn Healthcare SA, a Swiss pharmaceutical group, today announced that it has signed a Distribution and License Agreement for Aloxi® (Palonosetron hydrochloride) and Gelclair® in Germany with Riemser Arzneimittel AG, a medium-sized pharmaceutical group engaging in research, headquartered in ...
Lugano, Switzerland (ots) - Helsinn Healthcare SA, a Swiss pharmaceutical group, is pleased to announce, ahead of schedule, today's launch in the UK of Aloxi® (Palonosetron hydrochloride), a new generation treatment for chemotherapy induced nausea and vomiting, by its local partner Maelor plc, the specialist hospital medicines group. Aloxi® is a patented ...
Lausanne (ots) - The World Economic Forum has announced today the 39 visionary companies selected as Technology Pioneers 2008. Based in Lausanne, the Swiss company Anecova is one of them. The Technology Pioneers 2008 were nominated by the world's leading technology experts, including venture capitalists, technology companies, academics and media. The final selection ...
Lugano (ots) - Oral Formulations of 5-HT3 receptor Antagonists Represent Approximately 10% of the Day-of-Chemotherapy Market - Helsinn Healthcare SA, a privately owned Swiss pharmaceutical group, and its partner MGI PHARMA, INC., (Nasdaq: MOGN), a biopharmaceutical company focused in oncology and acute care, ...
Freising (ots) - Pieris AG (Munich, Germany) and Pepscan Therapeutics (Lelystad, Netherlands) today announced the commencement of a research collaboration aimed at identifying Anticalins® specific for G-Protein Coupled Receptors (GPCRs) and their development as therapeutic candidates. Pieris has pioneered ...
TRB Chemedica International S.A.
Geneva (ots) - TRB Chemedica International S.A. has issued legal proceedings against Gilead Science Limited in a dispute over the distribution rights of their products Viread, Hepsera, Truvada and Emtriva for Switzerland. TRB Chemedica International S.A., a small, family-owned Swiss pharmaceutical company based in Geneva, was granted exclusive rights by ...
Paris (ots) - At this year's 7th congress of the European Society of Gynaecology (Paris, 10-14 October 2007), the German pharmaceutical company Grunenthal GmbH presents the latest study results for its oral contraceptive Belara®. As the first of its kind the dermatological CEFIS-Study* of the University of Hamburg shows an impressive cosmetic improvement of impured skin due to the anti-androgenic properties of ...
Former Cedi-Diagnostics new affiliate for the Benelux and Nordic markets Zurich (ots) - Prionics, a world leader in farm animal diagnostics, enhances its own presence in Europe targeting the Benelux and Nordic markets with the launch of Prionics Lelystad (Netherlands). The latest affiliate emerges from the former Cedi-Diagnostics B.V. acquired in 2006, a spin-off from today's world-famous Animal Sciences Group of ...
Aachen (ots) - At this year's 4th World Congress of the World Institute of Pain (WIP), the German pharmaceutical company Grunenthal GmbH presented the latest clinical data on its centrally active analgesic tapentadol in acute pain. Tapentadol combines two analgesic principles in one molecule, μ-receptor ...
Winterthur/Switzerland (ots) - SpineLab AG, a privately held company, specialized in developing a dynamic stabilization system for the spine, announced today the strategic partnership with Precimed Group, a leading technology-driven supplier to the orthopaedic industry. Under this agreement, Precimed co-develops the minimally invasive instrument set and will exclusively handle production and logistics for ...
London (ots) - Helsinn's Top Management today announced the positive outcome of the EMEA procedure, according to Article 107, initiated due to concerns over serious liver problems. The Committee for Medicinal Products for Human Use (CHMP) today confirmed Nimesulide's positive benefit/risk profile. The benefits of these medicines outweigh their risks, but there ...
Basel (ots) - The 4th European Conference "Tobacco or Health" takes place in Basel from 11th-13th October, 2007. The conference is organized by the Swiss Cancer League together with the German Cancer Society on behalf of the Association of European Cancer Leagues. About 800 participants from over 60 countries ...
Freising-Weihenstephan, Germany (ots) - Pieris AG, a bio-pharmaceutical company developing Anticalins®, a novel class of targeted human protein therapeutics, today announced successful completion of a series of preclinical studies validating the use of Anticalins® in ophthalmologic disease. The studies reported by Pieris relate to PRS-055, an ...
Freising-Weihenstephan, Germany (ots) - Pieris AG, a bio-pharmaceutical company developing Anticalins®, a novel class of targeted human protein therapeutics, today announced successful completion of a series of preclinical studies validating the use of Anticalins® in ophthalmologic disease. The studies reported by Pieris relate to PRS-055, an Anticalin® ...
- Transaction creates a leading laboratory services group in Europe operating under the name "Unilabs" - Binding purchase agreement signed with Unilabs' majority shareholders to acquire 50.08% of the Unilabs voting rights and 38.10% of the capital - Intention to launch public tender offer at CHF 57.50 per Unilabs bearer Unanimous support of transaction by Unilabs Board of Directors ...
Plan-les-Ouates (ots) - Viroblock SA, a start-up dedicated to developing and commercializing a new generation of antiviral products, today announced that it has completed its first round of equity funding led by private investor Peter Pfister, Fongit Seed Invest SA, and Initiative Capital Romandie SA. Viroblock also announced that the newly appointed Board of Directors will consist of Peter Pfister (Chairman), ...
Aachen (ots) - The German pharmaceutical company Grunenthal announces its worldwide exclusive rights on trimegestone for the use in oral contraception by Aventis Pharma, SA, France, a subsidiary of sanofi-aventis. Thereby the firm extends its gynaecological pipeline. Trimegestone will be developed as a new oral contraceptive component derived from natural ...
European Society for Medical Oncology (ESMO)
PLEASE NOTE: FULL TEXT OF THE PRESS RELEASES AVAILABLE THROUGH WWW.ESMO.ORG/PRESSROOM upon registration PLEASE RESPECT INDIVIDUAL EMBARGO DATES/TIMES FOUND ON FULL PRESS RELEASES Lugano (ots) - HORMONE INHIBITOR PROMISING FOR HARD-TO-TREAT PROSTATE CANCER For prostate cancer patients whose tumors have continued to grow despite medical or surgical castration, a new ...
Freising-Weihenstephan, Germany (ots) - Pieris AG, a bio-pharmaceutical company developing Anticalins®, a novel class of targeted human protein therapeutics, announced today that its proprietary Duocalin® technology has successfully demonstrated dual targeting potential. Commenting on this development, Dr ...
Aachen (ots) - The German pharmaceutical company Grunenthal GmbH presented the first clinical evidence for the efficacy and tolerability of tapentadol ER (extended release) for patients suffering from chronic pain at the Annual Congress of the European League Against Rheumatism (EULAR), 13-16 June 2007, Barcelona, Spain. Tapentadol, a centrally acting analgesic, ...
pro adicta - escape Ambulatorium
Schoeftland (ots) - pro adicta facilitates the treatment of addiction to opioids such as heroin and methadone by means of escape, an innovative method of treatment using neuroelectric stimulation. Drug addiction can be overcome more easily using neuronal stimulation. On the basis of the latest knowledge in the ...
Barcelona (ots) - New Results Represent Additional Data From a Study Showing Superior Efficacy of ORENCIA or Infliximab Compared to Placebo at Six Months Bristol-Myers Squibb Company (NYSE: BMY) today announced additional study results providing evidence of the efficacy and durability of response of ORENCIA(R) (abatacept) through 12 months in adults with ...
Freising-Weihenstephan (ots) - Pieris AG, a bio-pharmaceutical company developing therapeutic products comprising of Anticalins®, a novel proprietary class of human binding proteins, announced today it has demonstrated potent anti-tumor activity of PRS-050. The positive results with PRS-050, a VEGF-specific ...
Bettlach (ots) - Mathys, the Bettlach-based orthopaedics business, recruited a further 28 persons in 2006. At 7.2 %, the increase in turnover was less than expected, but was nonetheless substantially higher than the industry average. This family-owned business achieved consolidated sales of CHF 74.2 million, which, although equivalent to a year-on-year increase of 7.2 %, was slightly less than expected. The slower ...
Aachen, Germany (ots) - Grünenthal GmbH announced that it has extended a licensing agreement with Ortho-McNeil Pharmaceutical, Inc. for tapentadol to include the Japanese market. Ortho-McNeil Pharmaceutical plans to arrange for the development of tapentadol for marketing in Japan. Ortho-McNeil"s affiliate, ...
Aachen, Germany (ots) - In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) has approved Versatis®, a novel 5 % lidocaine medicated plaster, for the treatment of neuropathic pain associated with previous herpes zoster infection (post-herpetic neuralgia, PHN), developed by the German drug company Grünenthal. Following this national approval of Versatis® and its national launch on January, ...